Synedgen
Biopharmaceutical company developing polymer-based therapeutics that target mucosal surfaces to treat inflammation, infection and tissue damage in pulmonary and gastrointestinal tracts. Activities include preclinical efficacy studies, formulation development for oral and topical delivery, academic and government collaborations, and preparation for clinical development and GMP readiness. Headquarters, research laboratories and a manufacturing facility are located in Claremont, CA.
Industries
Nr. of Employees
small (1-50)
Patents
Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US-12594296-B2
View DetailsMethods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US-12465616-B2
View DetailsMethods for treatment or prevention of damage resulting from radiation, trauma or shock
US-11975018-B2
View Details
Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US-12594296-B2
View DetailsMethods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US-12465616-B2
View DetailsMethods for treatment or prevention of damage resulting from radiation, trauma or shock
US-11975018-B2
View DetailsProducts
Orally delivered gastrointestinal mucosal repair therapeutic (clinic-ready candidate)
Oral polymeric formulation designed to restore GI mucosal integrity, reduce inflammation and mitigate radiation- or disease-induced GI injury; advanced to non-clinical efficacy testing.
Pulmonary mucolytic and anti-biofilm polymer candidate
Soluble, polycationic polysaccharide derivative developed to reduce sputum viscosity, disrupt bacterial biofilms and potentiate antibiotic activity in pulmonary systems.
Topical wound rinse for biofilm removal and wound healing
Polymer-based topical formulation developed to remove biofilms, prevent infection and stimulate dermal wound healing (preclinical development).
SYGN305
Drug candidate developed for the treatment of Radiation Mucositis and Radiation Proctitis.
SYGN309
Drug candidate developed for GI Infection.
SYGN313
Drug candidate developed for both acute and chronic inflammation of the GI tract, such as Crohn’s disease and inflammatory bowel disease (IBD).
Orally delivered gastrointestinal mucosal repair therapeutic (clinic-ready candidate)
Oral polymeric formulation designed to restore GI mucosal integrity, reduce inflammation and mitigate radiation- or disease-induced GI injury; advanced to non-clinical efficacy testing.
Pulmonary mucolytic and anti-biofilm polymer candidate
Soluble, polycationic polysaccharide derivative developed to reduce sputum viscosity, disrupt bacterial biofilms and potentiate antibiotic activity in pulmonary systems.
Topical wound rinse for biofilm removal and wound healing
Polymer-based topical formulation developed to remove biofilms, prevent infection and stimulate dermal wound healing (preclinical development).
SYGN305
Drug candidate developed for the treatment of Radiation Mucositis and Radiation Proctitis.
SYGN309
Drug candidate developed for GI Infection.
SYGN313
Drug candidate developed for both acute and chronic inflammation of the GI tract, such as Crohn’s disease and inflammatory bowel disease (IBD).
Services
Supplying investigational drug product for outsourced non-clinical efficacy and toxicology studies and coordinating with government and academic test sites.
Supplying investigational drug product for outsourced non-clinical efficacy and toxicology studies and coordinating with government and academic test sites.
Expertise Areas
- Mucosal therapeutics development
- Preclinical efficacy and toxicology studies
- Biopolymer/glycomics biomaterials
- Pulmonary mucolytics and anti-biofilm agents
Key Technologies
- Polymeric biomaterials (polysaccharide derivatives)
- Rheometry for sputum viscosity and elasticity
- In vitro biofilm disruption assays
- In vitro mucociliary transport and epithelial cell assays
News & Updates
Dr. Laura Saward promoted to Chief Executive Officer and Dr. Kenton Gregory appointed Chief Medical Officer.
Agreement to advance non-clinical efficacy testing of an active agent at government radiobiology research facilities with NIH support for study design and validation.
Received National Cancer Institute SBIR Phase I contract to demonstrate proof-of-concept activity of a polymer-based formulation to alleviate radiation proctitis.
Award from the National Heart Lung and Blood Institute to study a modified biopolymer that reduces sputum viscosity and biofilm cohesion for potential cystic fibrosis treatment.
Publication on effects of anti-retroviral lectins in adherence of Trichomonas vaginalis and related in vitro and in vivo results; includes contributions from company pharmaceutical manufacturing director.
U.S. Army provided supplemental funding to further preclinical research on a polysaccharide therapeutic that reduced mortality in animal radiation exposure studies.
Dr. Laura Saward promoted to Chief Executive Officer and Dr. Kenton Gregory appointed Chief Medical Officer.
Agreement to advance non-clinical efficacy testing of an active agent at government radiobiology research facilities with NIH support for study design and validation.
Received National Cancer Institute SBIR Phase I contract to demonstrate proof-of-concept activity of a polymer-based formulation to alleviate radiation proctitis.
Award from the National Heart Lung and Blood Institute to study a modified biopolymer that reduces sputum viscosity and biofilm cohesion for potential cystic fibrosis treatment.
Publication on effects of anti-retroviral lectins in adherence of Trichomonas vaginalis and related in vitro and in vivo results; includes contributions from company pharmaceutical manufacturing director.
U.S. Army provided supplemental funding to further preclinical research on a polysaccharide therapeutic that reduced mortality in animal radiation exposure studies.